Dyne Therapeutics is a clinical-stage company among biotech stocks that aims to treat rare, genetically driven diseases through its proprietary FORCE platform. It is currently developing therapies for ...

Mamma trodde han lå og sov, men 10-åringen lurte henne. Guttungen var besatt av å se nattkampene fra Mexico-VM. Med små, lette steg snek Kasper seg opp til rommet på hemsen. Forsiktig løftet han en ...

Analysts homed in on Duchenne muscular dystrophy and myotonic dystrophy type 1 assets during first quarter earnings as major players like REGENXBIO and Novartis as well as Dyne, Wave, Solid and ...

Dyne Therapeutics leverages its FORCE platform to target genetically driven muscle diseases with two lead clinical programs approaching pivotal milestones. DYNE-101 shows strong safety and functional ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Dyne Therapeutics, Inc. faces a pivotal 2026 with key milestones for DYNE-101 and DYNE-251, supported by a well-timed $350M equity raise. The recent offering extends DYN's cash runway by roughly one ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Dyne Therapeutics said Monday its ...

Dyne Therapeutics shares were higher Monday after Avidity Biosciences, a competitor developing drugs for neuromuscular disorders, agreed to be sold to Novartis for $12 billion. Dyne shares rose 41% to ...

DYNE-251 received FDA breakthrough therapy designation for DMD, showing promising clinical evidence of improvement over existing therapies. The DELIVER trial demonstrated sustained functional ...

Dyne Therapeutics, Inc. announced that it will present findings from its DELIVER and ACHIEVE clinical trials at the upcoming 2025 Muscular Dystrophy Association Clinical & Scientific Conference in ...

On Friday, Dyne Therapeutics, Inc. DYN revealed new data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1). Dyne plans to begin a global ...

Dyne Therapeutics, a clinical-stage company focused on therapeutics for genetically driven neuromuscular diseases, announced that it will present new clinical data from its Phase 1/2 ACHIEVE trial on ...